Clinical Research

In partnership with counterparts in the Democratic Republic of the Congo, FNL team monitors participant safety and ensures safety data integrity.

People with HIV on long-term antiretroviral therapy show signs of brain damage and cognitive impairment on a battery of imaging, laboratory, and functional tests, and they report a greater degree of difficulty with the routine tasks of everyday life, according to a new study. The study, published in April in the journal Neurology, is the first…

A research group that includes scientists from the Frederick National Laboratory for Cancer Research has shown that an experimental vaccine designed to simultaneously protect against malaria, Zika, and a host of other mosquito-borne diseases safely provokes a strong immune response when tested in human volunteers. The next step will be to see if…

The National Institutes of Health (NIH) awarded three Frederick National Laboratory teams with NIH Director’s Awards for innovative approaches to COVID-19-related research that advances knowledge and enhances health. “It is a tremendous honor for three Frederick National Laboratory teams to be nominated by three distinct entities within NIH…

Effort results in new community hospital sites for current and future studies.

A grim statistic is driving Steven Rosenberg’s mission to find new cancer treatments—and his partnership with Frederick National Laboratory (FNL) to do so. “Every year in the United States, about 600,000 people die of cancer, 90% of whom die of the solid epithelial cancers,” said Rosenberg, the M.D., Ph.D., chief of the National Cancer…

Victor Ssempijja remembers there being many fatherless households in his hometown in Uganda during his childhood. In fact, he says he could count the number of complete families on just his fingers. The other fathers had died of HIV and associated complications. “I actually grew up thinking that men were not supposed to live long,” he said…

The antiviral treatment remdesivir accelerated recovery time among hospitalized participants with advanced COVID-19 compared to participants who received placebo containing inactive ingredients, according to results of a clinical trial published May 22 in the New England Journal of Medicine. The median time to recovery was 11 days for…

In its urgent efforts to confront the novel coronavirus, the U.S. Food and Drug Administration (FDA) has tapped the Frederick National Laboratory for Cancer Research (FNL) to scientifically inform its decision-making on potential approval of blood tests for the presence of antibodies to SARS-CoV-2. FNL has an adaptive cancer research…

A team from the Frederick National Laboratory’s Biopharmaceutical Development Program is developing a new autologous cell therapy line that uses engineered chimeric antigen receptor (CAR) T cells to treat acute myeloid leukemia, a particularly aggressive form of pediatric blood cancer. This foray into cell immunotherapy represents a new avenue of…